Lecanemab Infusion Protocol and Monitoring

Management of Infusion Reactions

Mild reactions (Grade 1/2) should be managed by slowing or stopping the infusion rate, providing symptomatic treatment, and restarting at a reduced rate once stable, as recommended by the European Society for Medical Oncology 1, 2, 3
Severe reactions (Grade 3/4) require immediate cessation of the infusion, provision of aggressive symptomatic treatment including corticosteroids if needed, as per the guidelines from the European Society for Medical Oncology 1, 2, 3

Patients should be observed for a minimum of 1-2 hours after infusion completion, with education provided about potential delayed symptoms up to 24 hours post-infusion, according to the American College of Physicians 4